Clinical study of CL2020 in patients with acute respiratory distress syndrome associated with SARS-CoV-2 infection

Clinical study of CL2020 in patients with acute respiratory distress syndrome associated with SARS-CoV-2 infection - Clinical study of CL2020 in patients with acute respiratory distress syndrome associated with SARS-CoV-2 infection

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2043210005

Enrollment

Registered

2021-04-21

Start date

2021-04-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute respiratory distress syndrome

Interventions

Single intravenous administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -SARS-CoV-2 positive patients by RT-PCR -Patients diagnosed with ARDS by Berlin definition -Patients who are intubated and under mechanical ventilatory control

Exclusion criteria

Exclusion criteria: -Patients managed by Extracorporeal Membrane Oxygenation (ECMO) or using ventilation techniques such as High Frequency Oscillatory Ventilation (HFOV) -Patients who are not expected to survive for about 72 hours

Design outcomes

Primary

Measure	Time frame
STEP 1 : Safety as measured by incidence of Adverse events (AEs), adverse drug reactions (ADRs) STEP 2 : Efficacy as measured by mortality up to 4 weeks after administration	—

Contacts

Public ContactCall center

Life Science Institute, Inc.

lsii.chiken-inq@eppharmaline.co.jp+81-3-6748-7200

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026